Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy
Advanced Science · 2025
DOI: 10.1002/advs.202503979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jie Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, 266071, P. R. C…. Hauptthemen laut MEDLINE: Fulvestrant, Vitiligo, Immunotherapy, Melanoma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation of China, Youth Scholars of Higher Education of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Immunotherapy has revolutionized cancer treatment; however, only 10–30% of patients experience durable survival benefits, while most malignancies remain resistant. In melanoma, vitiligo‐like depigmentation is a frequent and generally mild immune‐related adverse event, whose presence correlates positively with enhanced antitumor immune responses and prolonged patient survival. By performing comparative analyses between vitiligo and melanoma, we established a biomarker panel—designated the vitiligo signature (VGS)—that differentiates “cold” from “hot” tumors with high accuracy. Leveraging a deep learning–based efficacy prediction system (DLEPS), we identified and validated Fulvestrant as a candidate capable of enhancing anti–programmed cell death ligand 1 (PD L1) therapy in preclinical models. Single cell RNA sequencing revealed that Fulvestrant expanded cytotoxic T cell populations, while immunofluorescence and flow cytometry confirmed markedly increased CD8⁺ T cell infiltration into tumor tissue. Mechanistic investigations demonstrated that Fulvestrant activates the C─C motif chemokine 5 (CCL5), major histocompatibility complex class I (MHC I), and type II interferon (IFN II) signaling pathways, thereby potentiating antitumor immunity. Collectively, our study introduces a precision approach for patient stratification in immunotherapy and highlights Fulvestrant as a promising component of immunotherapy based combination strategies warranting clinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, 266071, P. R. China.
- Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, 00100, Finland.
- Peking University International Cancer Institute, Peking University‑Yunnan Baiyao International Medical Research Center, State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmac…
ORCID-Profile: Zhengwei Xie, Peipei Shan, Sujie Zhu
Förderung
- National Science Foundation of China
- Youth Scholars of Higher Education of Shandong Province
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhu, J., Huang, L., Bi, S., Kong, W., Feng, W., Li, Y., Xie, Z., Shan, P., & Zhu, S. (2025). Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy. Advanced Science. https://doi.org/10.1002/advs.202503979
Vancouver
Zhu J, Huang L, Bi S, Kong W, Feng W, Li Y, et al. Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy. Advanced Science. 2025. doi:10.1002/advs.202503979
BibTeX
@article{Zhu2025,
author = {Zhu, Jie and Huang, Liting and Bi, Suzhen and Kong, WeiKaixin and Feng, Wanting and Li, Yingjia and Xie, Zhengwei and Shan, Peipei and Zhu, Sujie},
title = {Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202503979}
}
EUVIMED